Hans Guy, Schmidt Brian L, Strichartz Gary
Multidisciplinary Pain Center (PCT), Antwerp University Hospital (UZA), Wilrijkstraat 10, 2650 Edegem, Belgium.
Brain Res Rev. 2009 Apr;60(1):36-42. doi: 10.1016/j.brainresrev.2008.12.008. Epub 2008 Dec 25.
The endogenous peptide endothelin-1 (ET-1), originally identified as a potent vasoconstrictor, plays a role in a number of painful conditions. In this review article we discuss the mechanisms that are essential for local sensitization by subcutaneously administered ET-1, and report evidence of ET-1's ability to sensitize distant regions of the body, through the central nervous system and, likely, coupling through the spinal cord. In addition, we will review the latest information on the role of ET-1 in cancerous and non-cancerous conditions. Cancer pain has indeed been shown to be attenuated by antagonists of endothelin receptors, and ET-1 is known to be secreted by cancer cells of many different histologic types. Furthermore, a growing body of evidence links increased expression and secretion of ET-1 to the occurrence of non-cancer related pain syndromes, such as inflammatory and neuropathic pain syndromes.
内源性肽内皮素-1(ET-1)最初被鉴定为一种强效血管收缩剂,在多种疼痛病症中发挥作用。在这篇综述文章中,我们讨论皮下注射ET-1引起局部致敏所必需的机制,并报告ET-1通过中枢神经系统使身体远处区域致敏的证据,且可能是通过脊髓进行耦合。此外,我们将综述ET-1在癌症和非癌症病症中作用的最新信息。事实上,内皮素受体拮抗剂已被证明可减轻癌痛,并且已知ET-1由许多不同组织学类型的癌细胞分泌。此外,越来越多的证据表明ET-1表达和分泌的增加与非癌症相关疼痛综合征的发生有关,如炎症性和神经性疼痛综合征。